Ingrid A. Mayer, M.D.

Associate Professor

ingrid.mayer@vanderbilt.edu

Visit Lab Site


Faculty Appointments
Associate Professor of Medicine
Education
M.S.C.I., Science in Clinical Investigation, Vanderbilt University, Nashville, TennesseeM.D., Medicine, Universidade de Sao Paulo, Sao Paulo, Brazil
Office Address
Vanderbilt - Ingram Cancer Center
777 Preston Research Building
2220 Pierce Ave.
Nashville, TN 37232
Research Description
Dr. Mayer research endeavors have been focused on 1) the identification of targetable pathways in breast cancer, 2) ErbB signaling and endocrine therapy resistance in estrogen receptor positive (ER+) breast cancers, 3) PI3K signaling and endocrine therapy resistance in ER+ breast cancers, 4) chemotherapy resistance in triple negative breast cancers, and 5) biomarker prediction of treatment response in human breast cancers.
Identification of targetable pathways in breast cancer. To enhance understanding of breast cancer biology and to elucidate molecular determinants of clinical efficacy, Dr. Mayer obtained a Vanderbilt Physician Scientist Development (VPSD) Award. The specific aims of this grant were to identify relevant tumor antigens by multidimensional liquid chromatography (LC) and tandem mass spectrometry (MS) using antibodies raised against specific peptide motifs recognized by circulating IgGs in breast cancer patients sera and to determine if these tumor antigens could be detected by immunohistochemistry in all different subsets of primary breast tumors. Preliminary results of this work led to testing of new therapeutic strategies targeting the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in triple-negative, hormone-refractory and HER2-overexpressing refractory breast cancers, using biologically-based targeted agents. Initially, Dr. Mayer conducted a pilot project to determine the safety of an oral mTOR inhibitor in combination with an EGFR inhibitor in patients with metastatic breast cancer, addressing the synergism between EGFR and PI3K pathways. This study was partially funded by a Breast Cancer SPORE Pilot Project Grant. The outcome from this pilot project served as the preliminary data for her K23 Career Development Award. This grant included molecular analysis of individual breast cancers to determine how the biology of the cancer affects the response to the therapeutic agent.
ErbB signaling and endocrine therapy resistance in ER+ breast cancers. Preclinical models and some clinical observations suggest that ER+ breast cancers initially inhibited by a selective estrogen-receptor modulator (SERM) can use autocrine ErbB signaling in order to escape SERM action. This mechanism involves crosstalk between growth factor signaling and ER. Dr. Mayer obtained a Breast Cancer Research Foundation American Association for Cancer Research (BCRF-AACR) Grant for Translational Breast Cancer Research to explore if clinically combining an aromatase inhibitor with an EGFR/HER2 inhibitor would restore sensitivity to endocrine treatment in ER+/HER2+ breast cancers and would prevent the emergence of cells resistant to endocrine therapy. As a continuation of this work, funds were also obtained through the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 1 to determine 1) if combined neoadjuvant breast cancer therapy with the aromatase inhibitor letrozole and the HER2 tyrosine kinase inhibitor lapatinib induces pathologic complete responses in hormone receptor-positive breast cancers that overexpress HER2 and 2) to establish biomarkers predictive of response to this therapy, 3) to determine if the post-letrozole Ki67 in hormone receptor-positive/HER2-negative tumors mirrored the recurrence score as measured by RT-PCR of 21 selected genes in formalin-fixed tumor tissue sections, and 4) to use these biomarkers to discover gene expression signatures associated with response or resistance to estrogen deprivation.
PI3K signaling and endocrine therapy resistance in ER+ breast cancers. Preclinical and a few clinical studies have already suggested that ER+/PI3K mutant tumors exhibit a lower response to antiestrogens compared to ER+/PI3K wild-type tumors. Upon recent renewal of the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 1, Dr. Mayer is seeking to explore if the combination of antiestrogens with a PI3K inhibitor would be more effective against ER+/PI3K mutant
Research Keywords
Breast Cancer - Targeted Therapies
Clinical Research Keywords
Breast Cancer - Targeted Therapies
Publications
Mayer IA, Arteaga CL. PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer? [editorial]. J. Clin. Oncol. 2014 Sep 9/20/2014; 32(27): 2932-4. PMID: 25071103, PII: JCO.2014.55.9591, DOI: 10.1200/JCO.2014.55.9591, ISSN: 1527-7755.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.

Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol [print-electronic]. 2014 Apr 4/20/2014; 32(12): 1202-9. PMID: 24663045, PMCID: PMC3986383, PII: JCO.2013.54.0518, DOI: 10.1200/JCO.2013.54.0518, ISSN: 1527-7755.

Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med [print-electronic]. 2014 Apr; 71(4): 1592-602. PMID: 23661583, PMCID: PMC3742614, DOI: 10.1002/mrm.24782, ISSN: 1522-2594.

Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin. Cancer Res. 2014 Feb 2/15/2014; 20(4): 782-90. PMID: 24536073, PMCID: PMC3962777, PII: 1078-0432.CCR-13-0583, DOI: 10.1158/1078-0432.CCR-13-0583, ISSN: 1078-0432.

Yamaguchi NH, Mayer IA, Malzyner A, de Andrade CJ, Murad AM, Del Giglio A, Alves V. Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. J Gastrointest Oncol. 2014 Feb; 5(1): 57-66. PMID: 24490043, PMCID: PMC3904021, PII: jgo-05-01-057, DOI: 10.3978/j.issn.2078-6891.2013.056, ISSN: 2078-6891.

Lenneman CG, Abdallah WM, Smith HM, Abramson V, Mayer IA, Silverstein C, Silverstein C, Means-Powell J, Paranjape SY, Lenihan D, Sawyer DB, Raj SR. Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?. Ecancermedicalscience. 2014; 8: 446. PMID: 25114718, PMCID: PMC4118731, PII: can-8-446, DOI: 10.3332/ecancer.2014.446, ISSN: 1754-6605.

Mayer IA. Subtyping of triple-negative breast cancer. Clin Adv Hematol Oncol. 2013 Nov; 11(11): 731-2. PMID: 24896546, ISSN: 1543-0790.

Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer [print-electronic]. 2013 Jul 7/1/2013; 119(13): 2375-82. PMID: 23575918, PMCID: PMC3687009, DOI: 10.1002/cncr.28016, ISSN: 1097-0142.

Mayer I. Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol. 2013 Apr; 11(4): 217-24. PMID: 23604238, PMCID: PMC3774138, ISSN: 1543-0790.

Iams W, Beckermann KE, Neff AT, Mayer IA, Abramson VG. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Med. Oncol [print-electronic]. 2013; 30(2): 568. PMID: 23564368, PMCID: PMC3774143, DOI: 10.1007/s12032-013-0568-x, ISSN: 1559-131X.

Geisberg CA, Abdallah WM, da Silva M, Silverstein C, Smith HM, Abramson V, Mayer I, Means-Powell J, Freehardt D, White B, Lenihan D, Sawyer DB. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. J. Card. Fail. 2013 Jan; 19(1): 10-5. PMID: 23273589, PMCID: PMC3562720, PII: S1071-9164(12)01361-9, DOI: 10.1016/j.cardfail.2012.11.006, ISSN: 1532-8414.

Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Mol. Cancer Ther [print-electronic]. 2012 Oct; 11(10): 2301-5. PMID: 22879364, PMCID: PMC3682668, PII: 1535-7163.MCT-12-0511, DOI: 10.1158/1535-7163.MCT-12-0511, ISSN: 1538-8514.

Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Magn Reson Med [print-electronic]. 2012 Jul; 68(1): 261-71. PMID: 22127821, PMCID: PMC3291742, DOI: 10.1002/mrm.23205, ISSN: 1522-2594.

Abramson VG, Mayer IA. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Ther Adv Med Oncol. 2012 May; 4(3): 139-47. PMID: 22590487, PMCID: PMC3349077, PII: 10.1177_1758834012440834, DOI: 10.1177/1758834012440834, ISSN: 1758-8359.

Li X, Abramson RG, Arlinghaus LR, Chakravarthy AB, Abramson V, Mayer I, Farley J, Delbeke D, Yankeelov TE. An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results. EJNMMI Res. 2012; 2(1): 62. PMID: 23157877, PMCID: PMC3520720, PII: 2191-219X-2-62, DOI: 10.1186/2191-219X-2-62, ISSN: 2191-219X.

Abramson VG, Mayer IA. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer. Curr Treat Options Oncol. 2011 Dec; 12(4): 403-11. PMID: 21918859, DOI: 10.1007/s11864-011-0164-2, ISSN: 1534-6277.

Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, Kelley MC, Meszoely IM, Means-Powell JA, Abramson VG, Grau AM, Gore JC, Yankeelov TE. A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer. Phys Med Biol [print-electronic]. 2011 Sep 9/7/2011; 56(17): 5753-69. PMID: 21841212, PMCID: PMC3176673, PII: S0031-9155(11)87575-5, DOI: 10.1088/0031-9155/56/17/018, ISSN: 1361-6560.

Arlinghaus LR, Welch EB, Chakravarthy AB, Xu L, Farley JS, Abramson VG, Grau AM, Kelley MC, Mayer IA, Means-Powell JA, Meszoely IM, Gore JC, Yankeelov TE. Motion correction in diffusion-weighted MRI of the breast at 3T. J Magn Reson Imaging. 2011 May; 33(5): 1063-70. PMID: 21509862, PMCID: PMC3081111, DOI: 10.1002/jmri.22562, ISSN: 1522-2586.

Mayer IA, Arteaga CL. Does lapatinib work against HER2-negative breast cancers?. Clin. Cancer Res [print-electronic]. 2010 Mar 3/1/2010; 16(5): 1355-7. PMID: 20179241, PMCID: PMC3448974, PII: 1078-0432.CCR-09-3223, DOI: 10.1158/1078-0432.CCR-09-3223, ISSN: 1078-0432.

Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res [print-electronic]. 2010 Jan 1/15/2010; 16(2): 681-90. PMID: 20068102, PMCID: PMC2892225, PII: 1078-0432.CCR-09-1091, DOI: 10.1158/1078-0432.CCR-09-1091, ISSN: 1078-0432.

Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin. Cancer Res. 2009 Dec 12/15/2009; 15(24): 7479-91. PMID: 20008848, PMCID: PMC3471537, PII: 15/24/7479, DOI: 10.1158/1078-0432.CCR-09-0636, ISSN: 1078-0432.

Li X, Dawant BM, Welch EB, Chakravarthy AB, Freehardt D, Mayer I, Kelley M, Meszoely I, Gore JC, Yankeelov TE. A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response. Magn Reson Imaging [print-electronic]. 2009 Nov; 27(9): 1258-70. PMID: 19525078, PMCID: PMC2763059, PII: S0730-725X(09)00086-1, DOI: 10.1016/j.mri.2009.05.007, ISSN: 1873-5894.

Planey CR, Welch EB, Xu L, Chakravarthy AB, Gatenby JC, Freehardt D, Mayer I, Meszeoly I, Kelley M, Means-Powell J, Gore JC, Yankeelov TE. Temporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancer. J Magn Reson Imaging. 2009 Jul; 30(1): 121-34. PMID: 19557727, PMCID: PMC2782711, DOI: 10.1002/jmri.21812, ISSN: 1053-1807.

Mayer IA. Treatment of HER2-positive metastatic breast cancer following initial progression. Clin. Breast Cancer. 2009 Jun; 9 Suppl 2: S50-7. PMID: 19596643, PMCID: PMC3457066, PII: 7814858263518816, DOI: 10.3816/CBC.2009.s.005, ISSN: 1938-0666.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC, . Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2): 122-92. PMID: 19200416.

Mayer IA, Burris HA, Bendell JC, Means-Powell J, Arteaga CL, Shyr Y, Pietenpol JA.. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. 32nd Annual San Antonio Breast Symposium, San Antonio, TX. 2009; abstract 3093.

Mayer IA, Means-Powell J, Shyr Y, Arteaga CL. A phase Ib trial of Erlotinib, and EGFR inhibitor, and Everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. 32nd Annual San Antonio Breast Symposium, San Antonio, TX. 2009; abstract 3094.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J. Clin. Oncol [print-electronic]. 2008 Feb 2/20/2008; 26(6): 897-906. PMID: 18180460, PII: JCO.2007.13.5939, DOI: 10.1200/JCO.2007.13.5939, ISSN: 1527-7755.

Guix M, Mayer IA, Meszoely IM, Arteaga CL. Evaluation of biological agents targeted at early-stage disease. Breast Cancer Res [print-electronic]. 2008; 10 Suppl 4: S25. PMID: 19128439, PMCID: PMC2614851, PII: bcr2185, DOI: 10.1186/bcr2185, ISSN: 1465-542X.

Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging [print-electronic]. 2007 Jan; 25(1): 1-13. PMID: 17222711, PMCID: PMC2634832, PII: S0730-725X(06)00289-X, DOI: 10.1016/j.mri.2006.09.006, ISSN: 0730-725X.

Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin. Cancer Res. 2006 Mar 3/1/2006; 12(5): 1570-6. PMID: 16533783, PII: 12/5/1570, DOI: 10.1158/1078-0432.CCR-05-2304, ISSN: 1078-0432.

Mayer IA. Targeting cytokine receptors and pathways in the treatment of breast cancer. Cancer Treat. Res. 2005; 126: 243-62. PMID: 16209069, ISSN: 0927-3042.

Rouch D, Mayer I, Truica C. Barriers to chemoprevention of breast cancer with tamoxifen. American Society of Clinical Oncology Proceedings. 2005; 41th Annual Meeting: abst 1010.

Mayer IA. Cytokines and Cancer. [place unknown: publisher unknown]; 2005. (chapter 10).

Yamaguchi NH, Mayer IA, Malzyner A, Andrade CJC, Murad AM, Giglio AD, Cardoso H.. A pilot feasibility study of gefitinib (ZD1839) and celecoxib in metastatic GI tumors. ASCO Proceedings. 2004; 40th Annual Meeting(()): Abstract No 3086.

Costa FP, Schemerling R, Costa OF, Costa PA, Albertotti C, Martins S, Buzaid AC, Maluf F, Mayer I, Marques R. Intra-hepatic lipiodol I-131 combined with oxaliplatin, infusional FUDR, leucovorin in hepatocarcinoma and hepatic metastasis. ASCO Proceedings. 2004; 40th Annual Meeting(()): Abstract No 4133.

Chakravarthy B, Kelley M, McLaren B, Truica C, Mayer I, Brown C, Johnson K, Simpson J, Billheimer D, Pietenpol JA. Developing markers of therapeutic response using serial core biopsies to paclitaxel/radiation in stage II/III breast cancer. Breast Cancer Research and Treatment. 2004; supplement 1 (San Antonio Breast Cancer Symposium ¿ 27th Annual Meeting - Special Issue)((88)): S50 (abstract 1028).

Mayer IA. Manual de Oncologia Clínica - Hospital Sírio Libanês - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores. [place unknown: publisher unknown]; 2004. (2nd edition).

Mayer IA. Manual de Oncologia Clínica - Hospital Sírio Libanês - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores. [place unknown: publisher unknown]; 2004. (2nd edition).

Costa FC, Marques RJ, Mayer IA, Maluf FC, Martins SC, Cutait R, Buzaid AC. Irinotecan, Oxaliplatin and Raltitrexed every two weeks in untreated metastatic colorectal cancer patients. ASCO Proceedings. 2002; 38th Annual Meeting: Abstract No 2348.

Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J. Biol. Chem [print-electronic]. 2001 Jul 7/27/2001; 276(30): 28570-7. PMID: 11353767, PII: M011685200, DOI: 10.1074/jbc.M011685200, ISSN: 0021-9258.

Grumbach IM, Mayer IA, Uddin S, Lekmine F, Majchrzak B, Yamauchi H, Fujita S, Druker B, Fish EN, Platanias LC. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. Br. J. Haematol. 2001 Feb; 112(2): 327-36. PMID: 11167825, PII: bjh2556, ISSN: 0007-1048.

Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokoch GM, Fish EN, Platanias LC. The Rac1/p38 Map kinase pathway is required for IFN-alpha dependent transcriptional activation but not serine phosphorylation of STAT-proteins. J Biol Chem. 2000; 275((36)): 27634-40.

Mayer IA, Grumbach IM, Fujita S, Uddin S, Platanias LC. Activation of the p38 Map kinase pathway mediates the growth inhibitory effects of IFN-alpha in Chronic Myelogenous Leukemia. Blood. 2000; 96((11)): Abstract No 1500.

Available Postdoctoral Position Details
Posted: 9/22/2014
Not available